Physician profile
Christopher D Wells
NPI 1285618454
$2,773.55
in general payments reported to CMS, 2019-2025
25 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $299 · 2021: $214 · 2022: $434 · 2023: $437 · 2024: $494 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,276.06 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Gilead Sciences, INC. | $180.20 | 2019-2020 | |
| Janssen Biotech, INC. | $178.67 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $141.28 | 2020-2025 | Entyvio |
| Pfizer INC. | $139.05 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $123.37 | 2019-2024 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.86 | 2019-2023 | Xifaxan |
| Aimmune Therapeutics, INC. | $79.16 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $76.43 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $59.54 | 2019-2023 | Injectafer |
| Nestle Healthcare Nutrition INC. | $56.66 | 2020-2023 | |
| Celgene Corporation | $52.10 | 2023 | Zeposia |
| Qol Medical, LLC | $48.80 | 2023 | Sucraid |
| Amag Pharmaceuticals, INC. | $37.86 | 2021-2022 | |
| Braintree Laboratories, INC. | $30.31 | 2023-2025 | Suflave, Sutab |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $27.24 | 2024 | Idacio |
| Pharmacosmos Therapeutics INC. | $25.18 | 2025 | Monoferric |
| Genzyme Corporation | $24.78 | 2022 | |
| Enterra Medical, INC. | $20.86 | 2025 | |
| Ardelyx, INC. | $19.11 | 2024 | Ibsrela |
| Lilly USA, LLC | $15.86 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.84 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $15.64 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.63 | 2022 | |
| Medtronic, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.